Logo Image
|Articles|June 15, 2002

BioPharm International

  • BioPharm International-06-01-2002
  • Volume 15
  • Issue 6

Creating Effective Biopharmaceutical QA/QC Organizations: Your People are the Key

by Edward R. Arling, Ralph Dillon, and Joseph Noferi, Pharmacia GS API Biopharma Bringing a drug product to market requires that all parts of the manufacturing and validation puzzle comply with an increasing number of regulations. Managing the quality aspects for far-flung organizations can be a colossal assignment. A quality assurance unit may be the answer you need, along with finding capable, competent people and ensuring that they have the right communication tools.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 24 years ago

Negotiating and Structuring Strategic Alliances

over 24 years ago

Finding Funding in Biotechnology: Keeping the Companies Alive

over 24 years ago

Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of Your Patent Portfolio

over 24 years ago

Guest Editorial: Enabling Collaboration in the Pharmaceutical Industry

over 24 years ago

Stem Cells and Xenotransplantation: Ethics, Patents, and Politics

over 24 years ago

Unlocking the Value of R&D: Managing the Risks

over 24 years ago

Viewpoint: United Kingdom highlights biomanufacturing capabilities

over 24 years ago

Inside Washington: Safety, Risk, and Biotechnology Regulation

over 24 years ago

Criminal Penalties for Theft of Biological Material

over 24 years ago

Outsourcing Outlook: E-Procurement - Reverse Auctions and the Seller's Perspective.

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more